Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

Delayed Quote. Delayed  - 07/28 04:22:25 pm
6.86 USD   +0.29%
07/13 SPECTRUM PHARMA : Settles FOLOTYN® (pralatrexate injection) ANDA Pat..
07/11 SPECTRUM PHARMA : Biotechnology Stocks Under the Scanner -- PTC Ther..
07/06 SPECTRUM PHARMA : to Present Corporate Update at the Cantor Fitzgera..
News SummaryMost relevantAll newsSector news 

Spectrum Pharmaceuticals, Inc. : Hagens Berman Reminds Spectrum Pharmaceuticals Investors of May 13, 2013, Deadline in Securities Lawsuit

share with twitter share with LinkedIn share with facebook
share via e-mail
04/03/2013 | 03:35pm CEST

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) investors of the May 13, 2013, lead plaintiff deadline in a pending lawsuit filed on their behalf. Investors who suffered financial losses can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing SPPI@hbsslaw.com.

The lawsuit filed in U.S. District Court identifies a class of Spectrum investors who purchased stock in the company between August 8, 2012, and March 12, 2013, inclusive (the "class period"). Investors who wish to move to be a lead plaintiff in the case may also contact the firm by calling (510) 725-3000 and must move the court no later than May 13, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

On March 12, 2013, Spectrum disclosed to investors that it would significantly lower its 2013 revenue guidance on concerns that sales of its drug FUSILEV would be lower than expected. Following the disclosure, Spectrum's stock price fell dramatically, from a close of $12.43 per share on March 12 to a close of $7.79 per share on March 13. The stock has continued to trade at or around $7.00 since the disclosure.

Hagens Berman's investigation centers around whether Spectrum knew and failed to disclose to investors concerns about the sales of FUSILEV.

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

More information about this investigation is available at http://www.hb-securities.com/investigations/SPPI.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm's securities law blog is at http://www.meaningfuldisclosure.com.

Firmani + Associates
Mark Firmani, 206-443-9357

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
07/13 SPECTRUM PHARMACEUTICALS : Settles FOLOTYN® (pralatrexate injection) ANDA Patent..
07/13 SPECTRUM PHARMACEUTICALS INC : Other Events (form 8-K)
07/11 SPECTRUM PHARMACEUTICALS : Biotechnology Stocks Under the Scanner -- PTC Therape..
07/06 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Cantor Fitzgerald'..
07/06 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Cantor Fitzgerald&..
07/01 SPECTRUM PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holde..
06/09 SPECTRUM PHARMACEUTICALS INC : Other Events (form 8-K)
06/09 SPECTRUM PHARMACEUTICALS : Highlights an Oral Presentation on Apaziquone at the ..
06/01 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Jefferies 2016 Hea..
05/31 SPECTRUM PHARMACEUTICALS INC : Other Events (form 8-K)
More news
Sector news : Biotechnology & Medical Research - NEC
03:28pDJU.S. HOT STOCKS : Hot Stocks to Watch
02:56pDJCELGENE : Lifts Guidance as Revlimid Sales Rise
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
07/13 Spectrum Pharmaceuticals settles Folotyn patent fight with Fresenius
06/09 Spectrum and Sandoz settle Folotyn patent patent suit, Sandoz OK to sell gene..
05/25 Spectrum Pharma settles Folotyn patent squabble with Teva
05/05 Spectrum Pharmaceuticals' (SPPI) CEO Rajesh Shrotriya on Q1 2016 Results - Ea..
05/05 Spectrum Pharmaceuticals beats by $0.18, beats on revenue
Financials ($)
Sales 2016 134 M
EBIT 2016 -56,1 M
Net income 2016 -84,4 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 3,53x
Capi. / Sales 2017 4,15x
Capitalization 473 M
More Financials
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Full-screen chart
Technical analysis trends SPECTRUM PHARMACE...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 9,33 $
Spread / Average Target 36%
Consensus details
EPS Revisions
More Estimates Revisions
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph G. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer, CAO & Executive VP
Stuart Mitchell Krassner Director
Anthony E. Maida Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%10 582
LONZA GROUP AG11.40%9 818
ALKERMES PLC-35.74%7 827
More Results